Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 61

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 61
---
6 Internal-use software1.8(0.7)$1.1 Customer relationships1.6(0.3)1.3 Trademarks6.1(1.3)4.8 Internal-use software (in-process)21.6— $21.6 Total intangible assets$591.2 $(328.8)$262.4 

11

Table of Contents

The Company recorded amortization expense during the respective periods for these intangible assets as follows:Three months endedMarch 31,(in millions)20252024Amortization of intangible assets$9.4 $10.8 

6.ACCRUED LIABILITIES

The Company's accrued liabilities at March 31, 2025 and December 31, 2024 were as follows:(in millions)March 31,2025December 31,2024Employee compensation and benefits$43.0 $57.4 Accrued taxes payable9.0 5.1 Refunds payable and reserves18.9 19.9 Accrued royalties6.0 6.5 Escrow Liability7.5 7.5 Other accrued liabilities27.7 22.6 Total accrued liabilities$112.1 $119.0 

7.LONG-TERM DEBT

On June 30, 2023, the Company entered into an asset-based revolving credit facility (the “ABL Facility”) with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0 million for a total maximum principal commitment of $115.0 million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $59.3 million and $39.6 million under the ABL Facility at March 31